Omdat we weinig tot geen sponsoren meer hebben laat ik deze maand elk artikel voorafgaan met deze mededeling om te proberen wat meer donateurs te krijgen of wellicht een sponsor te krijgen voor onze website:  

Ook in 2026 kunt u een gift / donatie gebruiken als aftrekpost bij de inkomstenbelasting, omdat wij een ANBI status hebben. Mocht u onze website waarderen dan wilt u misschien een gift / donatie overmaken naar onderstaand rekeningnummer met vermelding gift 2026. 

NL79 RABO 0372931138 t.n.v. Stichting Gezondheid Actueel in Terneuzen. BIC/SWIFTCODE RABONL2U. 


Zie ook in gerelateerde artikelen hiernaast of hieronder

19 november 2026:

Zie ook andere artikelen op onze website met durvalumab in de titel:  https://kanker-actueel.nl/NL/search.html?search_text=durvalumab&search_in=title&page=1

Zie ook andere artikelen op onze website met de titel buikvlieskanker in de titel: https://kanker-actueel.nl/NL/search.html?search_text=buikvlieskanker&search_in=title

19 november 2026: Bron: ESMO 2026

Durvalumab = Imfinzi toegevoegd aan een eerstelijnsbehandeling met carboplatine/paclitaxel bij patiënten met gevorderde of recidiverende buikvlieskanker = endometriumkanker gevolgd door een onderhoudsbehandeling met durvalumab, al dan niet in combinatie met de parpremmer olaparib = Lynparza geeft bij een tussentijdse analyse na een studie follow-up van 52 maanden een verbetering van de totale overleving (OS) in vergelijking met carboplatine/paclitaxel alleen. Grootste verschil was voor durvalumab + Olaparib  naast chemo: 51,1 maanden versus 39,6 maanden.

Bij een mediane follow-upduur van ongeveer 52 maanden voor alle deelnemende patiënten waarvan de helft (52,1 procent) kon worden geanalyseerd, bedroeg:
  • de mediane overall overleving 51,1 maanden in de groep die durvalumab plus olaparib ontving (n = 239), vergeleken met 39,6 maanden in de controlegroep (n = 241).
  • In de groep die alleen durvalumab ontving (n = 238), bedroeg de mediane overall overleving 40,7 maanden ten opzichte van de controlegroep 39,8 maanden.
  • Geen van beide vergelijkingen bereikte tot nu toe een statistiche significantie. (tweezijdige P < 0,0165 respectievelijk P < 0,0184).
  • De overlevingspercentages na 36 maanden bedroegen 63,4% in de groep met durvalumab plus olaparib, 55,5% in de groep met durvalumab en 52,0% in de controlegroep. 
Bijwerkingen:

De meest voorkomende bijwerkingen van graad 3 of hoger waren bloedarmoede - anemie (respectievelijk 24,8%, 16,2% en 14,4%), een verlaagd aantal neutrofielen (respectievelijk 14,7%, 11,5% en 15,3%) en neutropenie (respectievelijk 11,5%, 8,5% en 5,9%).


Hier het abstract zoals gepresenteerd op ESMO 2026:

LBA37 - Durvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 study

Speakers
  • Shannon N. Westin (Houston, United States of America)
Lecture Time
15:05 - 15:15
Authors
  • Shannon N. Westin (Houston, United States of America)
  • Kathleen N. Moore (Omaha, United States of America)
  • Hye Sook Chon (Tampa, United States of America)
  • Jung-Yun Lee (Seoul, Republic of Korea)
  • Jessica Thomes Pepin (Minneapolis, United States of America)
  • Michael Sundborg (Pinehurst, United States of America)
  • Shin Nishio (Kurume, Japan, Fukuoka)
  • Ke Wang (Tianjin, China)
  • Joseph De la Garza (San Antonio, United States of America)
  • Kristi Mcintyre (Dallas, United States of America)
  • Fernando Contreras Mejia (Bogota, Colombia)
  • Andreia Cristina De Melo (Rio de Janeiro, Brazil)
  • Dagmara Klasa-Mazurkiewicz (Gdansk, Poland)
  • Christos Papadimitriou (Athens, Greece, Attiki)
  • Marta Gil Martín (L'Hospitalet de Llobregat, Spain)
  • Birute Brasiuniene (vilnius, Lithuania)
  • Charlotte Chrispin (Northolt, United Kingdom)
  • Greg Rychlik (Cambridge, United Kingdom)
  • Els Van Nieuwenhuysen (Leuven, Belgium)
  • Todd D. Tillmanns (Germantown, United States of America)

Background

DUO-E (NCT04269200) demonstrated statistically significant and clinically meaningful progression-free survival (PFS) benefit with CP + D followed by D (CP+D) and CP + D followed by D + O (CP+D+O) vs CP in first-line a/rEC (intention-to-treat patient (pt) population; dual primary endpoints) at the primary PFS analysis. We report data from a prespecified interim OS analysis, other secondary efficacy endpoints and safety updates from data cutoff-2 (2 Feb 2026).

Methods

Pts were randomised 1:1:1 to CP, CP+D or CP+D+O. OS, time from randomisation to first/second subsequent therapy or death (TFST/TSST) and treatment discontinuation or death (TDT) were analysed in the ITT population and by mismatch repair (MMR) status (OS only). Safety was assessed in the safety analysis set.

Results

241, 238 and 239 pts were randomised to CP, CP+D and CP+D+O. At this interim OS analysis (52% maturity; median follow-up: 52 months in censored pts), there was a favourable though not statistically significant OS trend for CP+D (hazard ratio 0.87 [95% confidence interval (CI), 0.68–1.11; p=0.259]) and CP+D+O (HR 0.77 [95% CI, 0.60–0.98; p=0.037]) vs CP in the ITT population. For CP+D vs CP, OS was favourable in dMMR pts (median [m]OS not reached ). For CP+D+O vs CP, there were clinically meaningful improvements in mOS of 11.5 (ITT) and 8.0 months (pMMR; table). Consistent benefits in TFST, TSST and TDT vs CP were observed (ITT). Both regimens continue to demonstrate a manageable safety and tolerability profile, generally consistent with individual components, with no new concerns.

Conclusions

Favourable interim OS and secondary outcomes further support CP + durvalumab followed by durvalumab or durvalumab + olaparib as treatments for a/rEC. Pts continue to be followed for final OS and safety.

Interim OS

CP CP+D CP+D+O
ITT, events, n/N (%) 136/241 (56.4) 123/238 (51.7) 115/239 (48.7)
mOS (95% CI), mo 39.6 (30.3–49.2) 40.7 (34.7–57.9) 51.1 (44.2–NR)
HR (95% CI)*† 0.87 (0.68–1.11) p=0.259‡ 0.77 (0.60–0.98) p=0.037‡
dMMR, events, n/N (%) 24/49 (49.0) 17/46 (37.0) 13/48 (27.1)
mOS (95% CI), mo 50.2 (17.3–NR) NR (NR–NR) NR (NR–NR)
HR (95% CI)*† 0.57 (0.30–1.05) 0.43 (0.21–0.83)
pMMR, events, n/N (%) 112/192 (58.3) 106/192 (55.2) 102/191 (53.4)
mOS (95% CI), mo 37.8 (27.0–48.6) 38.3 (26.3–54.5) 45.8 (37.1–58.7)
HR (95% CI)*† 0.95 (0.73–1.24) 0.85 (0.65–1.11)

*vs CP. †Stratified (ITT)/unstratified (dMMR/pMMR) Cox proportional hazards models. ‡Stratified log-rank test.

Clinical trial identification

NCT04269200. Primary completion: 2024-07-08.

Editorial acknowledgement

Medical writing assistance was provided by Lewis C Rodgers, PhD, of Omnicom Health Medical Communications, and was funded by AstraZeneca.

Legal entity responsible for the study

AstraZeneca.

Funding

AstraZeneca.

Disclosure

S.N. Westin: Financial Interests, Personal, Advisory Board: AstraZeneca, Caris, Clovis Oncology/Pharma&, Corcept, Eisai, Gilead, GSK, Immunocore, Immunogen, Lilly/Loxo, Merck, Mereo, NGM Bio, Nuvectis, Roche/Genentech, Seagen, Verastem, Zentalis, ZielBio, Daiichi Sankyo, Incyte, PMV Pharmaceuticals, Ottimo, AbbVie, Bayer, Genmab, Pfizer; Financial Interests, Institutional, Research Grant: AstraZeneca, AvengeBio, Bayer, Bio-Path, Clovis/Pharma&, GSK, Jazz Pharma, Mereo, Novartis, Nuvectis, Roche/Genentech, Zentalis, Pfizer; Financial Interests, Institutional, Steering Committee Member: Daiichi Sankyo; Financial Interests, Institutional, Local PI: Loxo Oncology. K.N. Moore: Financial Interests, Institutional, Advisory Board, advisory board work for gynecologic trial: Aadi; Financial Interests, Personal, Advisory Board, advisory boards around AbbVie pipeline: AbbVie; Financial Interests, Personal, Advisory Board: BioNTech, AstraZeneca, duality, Eisai, GSK/Tesaro, immunogen, Merck, Mersana, Regeneron, Verastem, Zentalis, Corcept, Iovance Biotherapeutics, Janssen, Kivu, Whitehawk, BeOne, Genmab, Incyte, Pfizer, Tubulis; Financial Interests, Personal, Advisory Board, multiple advisory boards over the past 4 years for TDXd and RDXd: Daiichi Sankyo; Financial Interests, Personal, Advisory Board, advisory boards for wee-1 PKMYT: Schrodinger; Financial Interests, Personal, Invited Speaker, visiting professor in Japan: Takeda; Financial Interests, Personal, Advisory Board, advisory boards for TUB040: Tubulis; Financial Interests, Personal, Advisory Board, advisory boards for pipeline bispecifics: Zymeworks; Financial Interests, Institutional, Full or part-time Employment, this is salary: GOG Partners Associate Director; Financial Interests, Institutional, Full or part-time Employment: NRG Ovarian Cancer Chair; Financial Interests, Personal, Royalties: UP to Date; Financial Interests, Institutional, Coordinating PI, international CO-PI, local site PI: AstraZeneca; Financial Interests, Institutional, Coordinating PI: Immunogen, GSK/Tesaro, duality; Financial Interests, Institutional, Local PI: Daiichi Sankyo, Regeneron, Artios, verastem; Financial Interests, Local PI: TORL; Non-Financial Interests, Member of Board of Directors: GOG; Non-Financial Interests, Leadership Role, BOD: ASCO. H.S. Chon: Financial Interests, Personal, Advisory Board: Merck, AstraZeneca, Karyopharm, Verastem Oncology. J. Lee: Financial Interests, Personal, Invited Speaker: AstraZeneca, Takeda, MSD, Roche, AbbVie, GSK; Financial Interests, Personal, Advisory Board: Eisai, GI Innovation, Regeneron, Daiichi Sankyo, Genmab, Sutro, Seagen, AstraZeneca, AbbVie, Corcept, GSK, Lilly, Merck Serono, MSD; Financial Interests, Institutional, Local PI: Alkermes, AstraZeneca, BergenBio, Cellid, Clovis Oncology, Eisai, GI Innovation, ImmunoGen, Janssen, Merck, Mersana, MSD, Novartis, OncoQuest, Roche, Seagen, Synthon, Regeneron, Ascendis Pharma, Advenchen, BMS, Kelun, SUTRO, GSK, AbbVie, Kelun, Lilly, Pfizer, Torl-Bio; Financial Interests, Personal and Institutional, Local PI: BeiGene; Financial Interests, Personal, Steering Committee Member: AstraZeneca, OncoQuest, Seagen, ImmunoGen, MSD; Financial Interests, Institutional, Research Grant: ONO, Takeda, GSK; Financial Interests, Institutional, Other, Sub I: Corcept; Financial Interests, Institutional, Steering Committee Member: AbbVie; Financial Interests, Personal, Local PI: Zymeworks. M. Sundborg: Financial Interests, Other, Honoraria: GSK; Financial Interests, Speaker’s Bureau: GSK; Financial Interests, Other, Employment: GSK. F. Contreras Mejia: Financial Interests, Other, Honoraria: Amgen, AstraZeneca/Columbia, Bristol-Myers Squibb Colombia, Lilly, Janssen, MSD Oncology, Novartis Colombia; Financial Interests, Other, Consulting or Advisory Role: GSK; Financial Interests, Advisory Board: Bristol-Myers Squibb Colombia. A.C. De Melo: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol-Myers Squibb, GSK, Merck Sharp and Dohme, AbbVie, Daiichi Sankyo; Financial Interests, Personal, Invited Speaker: AstraZeneca, Bristol-Myers Squibb, GSK, Merck Sharp and Dohme, Novartis, Daiichi Sankyo, Madison; Financial Interests, Institutional, Local PI: Regeneron Pharmaceuticals, Novartis, Merck Sharp and Dohme, GSK, Bristol-Myers Squibb, AstraZeneca, Amgen, Daiichi Sankyo. D. Klasa-Mazurkiewicz: Financial Interests, Other, Travel, Accommodations, Expenses: AstraZeneca. C. Papadimitriou: Financial Interests, Personal, Advisory Board: AbbVie, GSK. M. Gil Martín: Financial Interests, Personal, Invited Speaker: MSD, GSK, Clovis; Financial Interests, Personal, Advisory Board: AstraZeneca. B. Brasiuniene: Financial Interests, Personal, Other, lecture, expert testimony; reimbursement of conference accomodation expenses: SIA; Financial Interests, Personal, Writing Engagement, editor work in the local journal: UAB; Financial Interests, Personal, Advisory Board, lecture - speaker, expert testimony; reimbursement of travel expenses: AstraZeneca Lietuva UAB; Financial Interests, Personal, Invited Speaker, lecture-speaker: Merck Serono UAB; Financial Interests, Personal, Advisory Board, lecture-speaker, writing engagement, expert testimony: Eli Lilly Lietuva UAB; Financial Interests, Personal, Advisory Board, meeting, conference, scientific programme organization, search for the speakers, chair of the meeting, speaker: Nacionalinis mokymų centras VŠĮ; Financial Interests, Personal, Invited Speaker, lecture-speaker, writing engagement, expert testimony: Ipsen pharma; Financial Interests, Personal and Institutional, Coordinating PI, working with clinical trial: EORTC ; Financial Interests, Personal, Local PI, working with clinical trial: Ergomed, AstraZeneca Lietuva UAB; Financial Interests, Personal, Steering Committee Member, SC member for ENGOT-EN10 clinical trial DUO-E: AstraZeneca; Financial Interests, Personal and Institutional, Local PI, work with clinical trial: labcorp Drug development; Financial Interests, Personal and Institutional, Local PI, work with clinical trials: NSGO, PSI CRO AG; Financial Interests, Personal, Other, expert testimony: IQVIA commercial; Non-Financial Interests, Member: Lithuanian society of oncologist; Non-Financial Interests, Member, member of gynecological cancer group and melanoma group: EORTC; Non-Financial Interests, Member, member of NSGO and NSGO-CTU scientific committee member: NSGO - Nordic Society of Gynecological oncology; Non-Financial Interests, Member, member: The society of Lithuanian medical oncologists; Non-Financial Interests, Member, a member of ESMO: ESMO; Other, Other, Assoc. Prof position: Vilnius University of Lithuania Faculty of Medicine. C. Chrispin: Financial Interests, Other, Employee: AstraZeneca. G. Rychlik: Financial Interests, Other, Employee: AstraZeneca. E. Van Nieuwenhuysen: Financial Interests, Institutional, Advisory Board: Regeneron, Oncoinvent, AstraZeneca, GSK, MSD, Eisai; Financial Interests, Institutional, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Local PI: Regeneron, Oncoinvent, Seagen, Merck, Novartis, Verastem Oncology, Bioncotech Therapeutics; Financial Interests, Institutional, Steering Committee Member: AstraZeneca, Verastem Oncology; Financial Interests, Institutional, Coordinating PI: AstraZeneca; Financial Interests, Institutional, Trial Chair: Merck Serono; Non-Financial Interests, Institutional, Product Samples: Eli Lilly; Other, Other, Travel: GSK, MSD, AstraZeneca. T.D. Tillmanns: Financial Interests, Other, Employment: West Clinic; Financial Interests, Leadership Role: Regional One Health, St Francid; Financial Interests, Other, Honoraria: AstraZeneca, Intuitive Surgical, GlaxoSmithKline, Eisai, Myriad Genetics; Financial Interests, Speaker's Bureau: Eisai, GlaxoSmithKline, AstraZeneca.


Plaats een reactie ...

Reageer op "Durvalumab naast carboplatine/paclitaxel, gevolgd door een onderhoudsbehandeling met alleen Durvalumab + eventueel olaparib = Lynparza geeft betere totale overleving bij buikvlieskanker als 1e lijnsbehandeling in vergelijking met alleen chemo"


Gerelateerde artikelen
 

Gerelateerde artikelen

Durvalumab naast carboplatine/paclitaxel, >> Rinatabart sesutecan, een >> Onderzoekers ontdekken waarom >> Overzichtstudie van vormen >> Pembrolizumab, een anti-PD >> Dendritische celtherapie aanvullend >> Immuuntherapie met avelumab, >> Nivolumab, immuuntherapie >> DMUC5754A een nieuw experimenteel >> Dendritische celtherapie blijkt >>